This page shows the latest relugolix news and features for those working in and with pharma, biotech and healthcare.
Their relugolix candidate has positive mid-stage results in endometriosis-related pain, uterine fibroids, and prostate cancer, and is currently in phase III testing with some results due next year.
Last year, Takeda and Myovant reported positive mid-stage results with their relugolix candidate in this indication as well as endometriosis-related pain and prostate cancer.
Axovant for example is developing a GSK cast-off for Alzheimer's disease - serotonin 5-HT6 receptor antagonist RVT-101 - through late-stage testing, while Myovant is working on relugolix, a
For its tie-up with Takeda, the Japanese firm has granted Myovant Sciences an exclusive, worldwide license for its prostate cancer candidate relugolix, with the exception of Asian markets. ... Andrew Plump, chief medical and scientific officer at Takeda,
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Wordbird is a healthcare communications agency with creative, compelling copy at its heart....